Lakefront Biotherapeutics (LKFT) Total Current Liabilities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Total Current Liabilities data on file, last reported at $117.6 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $117.6 million, down 74.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $117.6 million (down 74.43% YoY), and the FY2025 annual result was $177.9 million, down 50.31% from the prior year.
• Total Current Liabilities declined to $117.6 million in Q1 2026 per LKFT's latest filing, from $177.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $631.8 million in Q1 2022 and troughed at $117.6 million in Q1 2026.
• A 5-year average of $418.1 million and a median of $428.5 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities grew 11.1% in 2025, then plunged 74.43% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $533.1 million in 2022, then decreased by 20.04% to $426.3 million in 2023, then slipped by 16.0% to $358.1 million in 2024, then slumped by 50.31% to $177.9 million in 2025, then tumbled by 33.93% to $117.6 million in 2026.
• Business Quant data shows LKFT's Total Current Liabilities at $117.6 million in Q1 2026, $177.9 million in Q4 2025, and $428.5 million in Q3 2025.